Novartis pelacarsen fails 8,323-patient Phase 3 Lp(a)HORIZON cardiovascular trial
Novartis and Ionis say pelacarsen substantially reduced lipoprotein(a) but failed to reduce major cardiovascular events in the 8,323-patient Phase 3 Lp(a)HORIZON trial.